2022 American Transplant Congress
Selective CD28 Blockade Impacts T Cell Differentiation During Hematopoietic Reconstitution Following Lymphodepletion
*Purpose: Costimulation blockade targeting the CD28 pathway provides improved long-term transplant survival without the nephrotoxicity of calcineurin inhibitors. However, treatment with the CTLA-4Ig fusion protein…2022 American Transplant Congress
Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression
University of Utah Health, Salt Lake City, UT
*Purpose: The demand for kidney transplant continues to rise, and limited supply has encouraged acceptance of marginal donor organs, such as those at risk for…2022 American Transplant Congress
Co-stimulation Patways Pd-1 (the Programmed Death 1) And Icos (the Inducible T Cell Co-stimulator) In Peripheral Mononuclear Cells Mesured By Flow Cytometry As A Possible Tool In The Follow-up And Diagnosis Of Kidney Transplant Rejection.
Posgrado de Ciencias médicas, Universidad Nacional Autonoma de México, CDMX, Mexico
*Purpose: Currently, the follow-up of KT in the clinic remains the creatinine levels, this is a highly specific, however, without sensitivity to determine diagnosis of…2022 American Transplant Congress
Clinically Available Immunosuppressive Agents Prolong Pig-to-Primate Kidney Xenograft Survival
1Surgery, Duke Transplant Center, Durham, NC, 2eGenesis Inc, Cambridge, MA
*Purpose: Most immunosuppressive regimens used in Pig-To-Primate Xenotransplantation contain anti-CD154 agents, compounds that are currently not FDA-approved. The aim of this study was to assess…2022 American Transplant Congress
Longitudinal Characterization of Memory B Cells During Antibody Mediated Rejection Treated with Plasmapheresis, Bortezomib, and Belatacept in Heart Transplant Recipients
*Purpose: Donor specific antibodies (DSA) and antibody mediated rejection (AMR) continue to limit allograft longevity after heart transplant. Effective treatments are limited and often complicated…2022 American Transplant Congress
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study
*Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…2021 American Transplant Congress
Belatacept Pharmacokinetic Analysis Comparing Belatacept Early Steroid Withdrawal Trial (BEST) with Benefit and Benefit-ext Trials
*Purpose: Belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies where fixed mg/kg dosing compared a less intense(LI) and more intense(MI) regimen. LI was preferred…2021 American Transplant Congress
Belatacept Conversion in Elderly Renal Transplant Recipients
1UW Health, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI
*Purpose: Describe the impact of conversion from a calcineurin inhibitor (CNI) based immunosuppressive regimen to belatacept in elderly renal transplant recipients.*Methods: Adult renal transplant patients…2021 American Transplant Congress
Infectious Complications After Belatacept Conversion in Kidney Transplant
*Purpose: Tacrolimus (tac), a calcineurin inhibitor, is associated with multiple adverse effects when used for immunosuppression following kidney transplant (KT). Belatacept (bela) is a monoclonal…2021 American Transplant Congress
A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 30
- Next Page »